Evidence map›Paper›PMID 32624572›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2020

Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing.

My Linh Thibodeau, Kieran O'Neill, Katherine Dixon, Caralyn Reisle, Karen L Mungall, Martin Krzywinski, Yaoqing Shen, Howard J Lim, Dean Cheng, Kane Tse and 20 more

Abstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Rare solid tumours as indicators of hereditary cancer syndromes.European journal of human genetics : EJHG · 2026
    Review
  2. Review
  3. [Genetic diagnostics].Pathologie (Heidelberg, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

My Linh Thibodeau *Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Kieran O'Neill *Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Katherine Dixon *Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Caralyn ReisleCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Karen L MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Martin KrzywinskiCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Yaoqing ShenCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Howard J LimDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Dean ChengCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Kane TseCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Tina WongCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Eric ChuahCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Alexandra FokCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Sophie SunHereditary Cancer Program, BC Cancer, Vancouver, BC, Canada.
Daniel RenoufDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
David F SchaefferDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Carol CreminDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Stephen ChiaDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Sean YoungDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Pawan PandohCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Stephen PleasanceCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Erin PleasanceCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Andrew J MungallCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Richard MooreCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
Stephen YipDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Aly KarsanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Janessa LaskinDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.
Marco A MarraDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
Kasmintan A SchraderDepartment of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. ischrader@bccancer.bc.ca.ORCID http://orcid.org/0000-0002-7413-4314
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada. sjones@bcgsc.ca.

Funding

CIHR
6 · The paper itself

Abstract

purposeStructural variants (SVs) may be an underestimated cause of hereditary cancer syndromes given the current limitations of short-read next-generation sequencing. Here we investigated the utility of long-read sequencing in resolving germline SVs in cancer susceptibility genes detected through short-read genome sequencing.

methodsKnown or suspected deleterious germline SVs were identified using Illumina genome sequencing across a cohort of 669 advanced cancer patients with paired tumor genome and transcriptome sequencing. Candidate SVs were subsequently assessed by Oxford Nanopore long-read sequencing.

resultsNanopore sequencing confirmed eight simple pathogenic or likely pathogenic SVs, resolving three additional variants whose impact could not be fully elucidated through short-read sequencing. A recurrent sequencing artifact on chromosome 16p13 and one complex rearrangement on chromosome 5q35 were subsequently classified as likely benign, obviating the need for further clinical assessment. Variant configuration was further resolved in one case with a complex pathogenic rearrangement affecting TSC2.

conclusionOur findings demonstrate that long-read sequencing can improve the validation, resolution, and classification of germline SVs. This has important implications for return of results, cascade carrier testing, cancer screening, and prophylactic interventions.

Indexed as

Genetic Predisposition to DiseaseNeoplasmsBase SequenceGenomeHigh-Throughput Nucleotide SequencingHumansgenome sequencinghereditary cancerlong-read sequencingstructural variantsvariant interpretation

Identifiers

PMID32624572
PMCPMC7605438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.